Insider Trading activities of Advaxis, Inc. insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Advaxis, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Advaxis, Inc. since year 2005. Table 2 shows the detailed insider transactions of Advaxis, Inc. since 2005. The reporting company's ticker symbol is ADXS. The reporting company's CIK number is 1100397.
The total value of stock buying since 2005 is $20,044,072.
The total value of stock sales since 2005 is $10,815,901.
The total value of stock option exercises since 2005 is $163,132.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Advaxis, Inc. (ADXS).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-10 0 $0 600,000 $2,580,000 0 $0
2017-09 0 $0 1,239,323 $5,474,434 0 $0
2017-03 0 $0 2,454 $20,220 0 $0
2016-12 0 $0 17,836 $140,195 0 $0
2016-11 0 $0 11,037 $91,827 0 $0
2016-10 0 $0 19,162 $157,703 0 $0
2016-08 0 $0 56,569 $863,101 0 $0
2016-05 0 $0 15,122 $113,319 0 $0
2016-03 0 $0 17,325 $145,857 0 $0
2016-01 0 $0 11,917 $81,988 0 $0
2015-12 0 $0 14,332 $177,573 0 $0
2015-10 0 $0 55,034 $609,002 0 $0
2015-08 300,000 $4,253,300 0 $0 0 $0
2015-07 0 $0 11,392 $175,891 0 $0
2015-04 500,000 $9,500,000 0 $0 0 $0
2015-02 684,762 $5,135,715 0 $0 0 $0
2014-05 0 $0 14,530 $38,242 0 $0
2014-03 3,333 $9,999 0 $0 0 $0
2013-10 75,800 $303,200 0 $0 40,783 $163,132
2012-11 0 $0 677,632 $24,850 0 $0
2010-02 0 $0 760,624 $121,699 0 $0
2007-10 2,768,405 $418,312 0 $0 0 $0
2007-02 184,373 $29,499 0 $0 0 $0
2007-01 1,000,000 $200,000 0 $0 0 $0
2006-01 238,095 $44,047 0 $0 0 $0
2005-06 150,000 $150,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Advaxis, Inc. insiders (ADXS)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-10-11 Gross Phillip Sale 600,000 4.30 2,580,000
2017-09-26 Gross Phillip Sale 300,000 4.00 1,200,000
2017-09-25 Gross Phillip Sale 405,323 4.38 1,775,314
2017-09-22 Gross Phillip Sale 534,000 4.68 2,499,120
2017-03-31 Petit Robert (Chief Scientific Officer) Sale 2,454 8.24 20,220
2016-12-30 Bonstein Sara (Chief Financial Officer) Sale 5,520 7.37 40,682
2016-12-20 Mckearn Thomas J Sale 12,316 8.08 99,513
2016-11-02 Petit Robert (Chief Scientific Officer) Sale 2,797 8.32 23,271
2016-11-02 O'connor Daniel (Chief Executive Officer) Sale 8,240 8.32 68,556
2016-10-25 Mayes, Gregory T. (Chief Business Officer) Sale 19,162 8.23 157,703
2016-08-09 Sidransky David Sale 11,404 14.85 169,349
2016-08-09 Berman Richard J Sale 15,761 15.67 246,974
2016-08-08 Sidransky David Sale 11,404 15.17 172,998
2016-08-08 Berman Richard J Sale 18,000 15.21 273,780
2016-05-13 Mckearn Thomas J Sale 4,100 7.45 30,545
2016-05-02 Petit Robert (Chief Scientific Officer) Sale 2,785 7.51 20,915
2016-05-02 O'connor Daniel (Chief Executive Officer) Sale 8,237 7.51 61,859
2016-03-31 Petit Robert (Chief Scientific Officer) Sale 3,325 9.13 30,357
2016-03-16 Mckearn Thomas J Sale 14,000 8.25 115,500
2016-01-29 Petit Robert (Chief Scientific Officer) Sale 3,099 6.88 21,321
2016-01-29 O'connor Daniel (Chief Executive Officer) Sale 8,818 6.88 60,667
2015-12-17 Berman Richard J Sale 14,332 12.39 177,573
2015-10-30 Petit Robert (Chief Scientific Officer) Sale 2,867 12.26 35,149
2015-10-30 O'connor Daniel (Chief Executive Officer) Sale 8,350 12.26 102,371
2015-10-26 Mayes, Gregory T. (Chief Operating Officer) Sale 19,231 11.63 223,656
2015-10-20 Mauro David J (Chief Medical Officer) Sale 24,586 10.08 247,826
2015-08-24 Gross Phillip Buy 50,000 13.81 690,300
2015-08-21 Gross Phillip Buy 75,000 14.21 1,065,750
2015-08-20 Gross Phillip Buy 175,000 14.27 2,497,250
2015-07-31 Petit Robert (Chief Scientific Officer) Sale 2,943 15.44 45,439
2015-07-31 O'connor Daniel (Chief Executive Officer) Sale 8,449 15.44 130,452
2015-04-30 Gross Phillip Buy 500,000 19.00 9,500,000
2015-02-18 Gross Phillip Buy 684,762 7.50 5,135,715
2014-05-09 Berman Richard J Sale 14,530 2.63 38,242
2014-03-31 O'connor Daniel (Chief Executive Officer) Buy 3,333 3.00 9,999
2013-10-24 Petit Robert (Chief Scientific Officer) Buy 12,800 4.00 51,200
2013-10-24 O'connor Daniel (Chief Executive Officer) Buy 13,500 4.00 54,000
2013-10-24 Rosenblum Mark J (Chief Financial Officer) Buy 12,000 4.00 48,000
2013-10-24 Patton James P Buy 25,000 4.00 100,000
2013-10-24 Appel Roni Buy 12,500 4.00 50,000
2013-10-22 Moore Thomas A Option Ex 40,783 4.00 163,132
2012-11-23 Berman Richard J Sale 100,000 .04 3,500
2012-11-21 Berman Richard J Sale 277,632 .04 10,550
2012-11-20 Berman Richard J Sale 300,000 .04 10,800
2010-02-12 Berman Richard J (Director) Sale 760,624 .16 121,699
2007-10-25 Cobb Fredrick D (Vice President Finance) Buy 40,695 .18 7,325
2007-10-25 Rothman John F (VP Clinical Development) Buy 61,043 .18 10,987
2007-10-23 Moore Thomas A (CHAIRMAN / CEO) Buy 2,666,667 .15 400,000
2007-02-23 Cobb Fredrick D (Vice President Finance) Buy 49,641 .16 7,942
2007-02-23 Rothman John F (VP of Clinical Development) Buy 134,732 .16 21,557
2007-01-03 Appel Roni (Director) Buy 1,000,000 .20 200,000
2006-01-25 Appel Roni (Director) Buy 238,095 .18 44,047
2005-06-22 Appel Roni (Chief Financial Officer) Buy 150,000 1.00 150,000

Insider trading activities including stock purchases, stock sales, and option exercises of ADXS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Advaxis, Inc. (symbol ADXS, CIK number 1100397) see the Securities and Exchange Commission (SEC) website.